Susquehanna International Group
OBIO icon

Susquehanna International Group’s Orchestra BioMed OBIO Stock Holding History

Susquehanna International Group’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-60,100
Closed -$149K – 13209
2025
Q3 		$149K Buy
+60,100
New +$166K ﹤0.01% 11288

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Susquehanna International Group's OBIO Position: Q1 2026 in Review

Susquehanna International Group reduced its Orchestra BioMed (OBIO) stake by 37% in Q1 2026, selling an estimated $245K and leaving 97,521 shares worth $414K. The position accounts for ﹤0.01% of the portfolio, ranked #10128.

Susquehanna International Group first reported a position in OBIO in Q3 2023 and has held it in 7 quarters since. The position peaked at $644K in Q4 2025. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

  • Susquehanna International Group held 97,521 shares of Orchestra BioMed worth $414K as of Q1 2026.
  • Susquehanna International Group sold 57,609 Orchestra BioMed shares in Q1 2026, an estimated $245K.
  • Orchestra BioMed made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #10128 holding.
  • Susquehanna International Group first reported a position in Orchestra BioMed in Q3 2023 and has held it in 7 quarters since.
  • Susquehanna International Group's Orchestra BioMed position peaked at $644K in Q4 2025.
  • 65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.